Q2 2023 · 13F-HR
venBio Partners LLCholdings as filed
Filed 2023-08-14 · accession 0000905148-23-000738
$276.3M
Reported value
7
Positions
2023-06-30
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 00445A100 | — | ACELYRIN INC | $80.6M | 29.2% | 3,857,230 | Common | SOLE |
| 00166B105 | ALXO | ALX ONCOLOGY HLDGS INC | $72.8M | 26.4% | 9,699,925 | Common | SOLE |
| N69605108 | PHVS | PHARVARIS N V | $64.6M | 23.4% | 4,264,672 | Common | SOLE |
| 413197104 | HRMY | HARMONY BIOSCIENCES HLDGS IN | $36.4M | 13.2% | 1,035,396 | Common | SOLE |
| 92332V107 | VTYXUSD | VENTYX BIOSCIENCES INC | $13.9M | 5.03% | 424,032 | Common | SOLE |
| 28623U101 | — | ELEVATION ONCOLOGY INC | $4.4M | 1.60% | 2,914,255 | Common | SOLE |
| 45258K109 | — | IMPEL PHARMACEUTICALS INC | $3.5M | 1.27% | 2,759,791 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.